Biotech - Technical Analysis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (269)	3/24/2002 10:13:46 PM
From: Jibacoa	Read Replies (1) of 544

DNDN Seems to have bottomed at the 3.37 level.<g> It performed well on Friday after giving a buy signal for the 3rd time this past week.(It was not able to get past the 4.45 level on the previous two attempts.<g>)The OBV also has expanded nicely. siliconinvestor.com It seems now ready to close its January 11 down-gap. siliconinvestor.com As of December 31, 2001, Dendreon had approximately $81.2 million in cash and cash equivalents (Reportedly about $3.27 per share). They are conducting a Phase III for Ca of Prostate and a Phase II for Multiple Myeloma. According to the company: "In 2002, we look forward to analyzing the final results from the first of our double blind, placebo-controlled Phase III trials of Provenge and to the design of a Phase III protocol for our Mylovenge(TM) vaccine," "In addition to our therapeutic vaccines, we are excited about the potential opportunity of our monoclonal antibody candidates, including DN1924 and trp-p8, about which there has been considerable external interest, and look forward to advancing them toward the clinic." The insiders hold 70% and the institutions which hold 38% (127% of the float) reportedly bought 1.84M shares in the last Q. Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next